Unlisted Shares
Sigachi Laboratories Limited Unlisted Shares
Verified Unlisted CompanyOff-market Transfer · NSDL / CDSL
About Sigachi Laboratories Limited Unlisted Shares
Sigachi Laboratories Limited is engaged in manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates. The company operates in the pharmaceutical sector and also has investments in subsidiaries involved in logistics (ICDs, freight depots) and other related activities, making it a diversified business with exposure to pharma and infrastructure segments.
Share Details
| company Name | Sigachi Laboratories Limited Unlisted Shares |
| indicative Unlisted Share Price | ₹65 |
| market Capitalization | ₹35 Crore |
| lot Size | 1000 |
| 52 Week High | ₹52 |
| 52 Week Low | ₹52 |
| face Value | ₹10 |
| book Value | 58.39 |
| pe Ratio | 29.55 |
| pb Ratio | 0.89 |
| debt To Equity | 0 |
| return On Equity | 3.03 |
| total Outstanding Shares | 6753100 |
| isin | INEA8H01018 |
| depository | NSDL & CDSL |
| pan | AACCS8220M |
| cin | L24230TG1994PLC017876 |
| rta | Venture Capital and Corporate Investments |
Income Statement (Profit & Loss) (₹ in Crore)
| Particulars | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 260 | 195 | 374 | 312 |
| EBITDA | 211 | 142 | 242 | 109 |
| PBT | 238 | 173 | 281 | 152 |
| Net Profit / Loss (PAT) | 200 | 131 | 197 | 119 |
| EPS | 2.74 | 1.79 | 2.69 | 1.63 |
Key Financial Ratios (Last 3–5 Years)
| Ratio | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Operating Profit Margin (%) | 81.15 | 72.82 | 64.71 | 34.94 |
| Net Profit Margin (%) | 76.92 | 67.18 | 52.67 | 38.14 |
| Earning Per Share (Diluted) | 2.74 | 1.79 | 2.69 | 1.63 |
Financial Annual Report Summary
The company has shown fluctuating revenue and declining profitability margins over recent years. While it maintains a debt-free balance sheet, declining margins and low return ratios indicate operational inefficiencies.
Why Invest in Sigachi Laboratories Limited
- Revenue is volatile with no consistent growth trend.
- Margins declining sharply over the years.
- Debt-free balance sheet is a positive.
- Low ROE (~3%) indicates weak capital efficiency.
Balance Sheet - Assets (₹ in Crore)
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Fixed Assets | 229 | 237 | 321 | 310 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 2,151 | 1,966 | 2,663 | 2,978 |
| Trade Receivables | 16 | 1 | 20 | 3 |
| Inventory | 0 | 0 | 0 | 0 |
| Other Assets | 832 | 922 | 730 | 800 |
| Total Assets | 3,028 | 3,126 | 3,734 | 4,091 |
Balance Sheet - Liabilities & Equity (₹ in Crore)
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Share Capital | 731 | 731 | 731 | 731 |
| FV | 10 | 10 | 10 | 10 |
| Reserves | 2,244 | 2,343 | 2,870 | 3,202 |
| Borrowings | 0 | 0 | 0 | 0 |
| Trade Payables | 0 | 0 | 0 | 0 |
| Other Liabilities | 53 | 52 | 133 | 158 |
| Total Liabilities | 3,028 | 3,126 | 3,734 | 4,091 |
Liabilities Breakdown & Balance Sheet Insights
Balance Sheet Insights
Large portion of assets tied in investments rather than core operations.
Liabilities Breakdown
Debt to Equity ratio of 0 indicates debt-free structure.
Additional Insights
High investment allocation raises questions about core business focus.
Cash Flow Insights
- Operating cash flow is inconsistent and volatile.
- Investment-heavy balance sheet.
- No reliance on debt financing.
Shareholding Pattern
Recent
Promoter: High
Institutional: Low
Public: Low
Promoters & Management
Promoter-led pharmaceutical business with diversification into investments and logistics.
Key Management
Not Available
Registrar & Transfer Agent (RTA)
Registrar: Venture Capital and Corporate Investments
Management Analysis
Focus appears divided between pharma operations and investment activities.
Frequently Asked Questions About Sigachi Laboratories Limited Unlisted Shares
Explore More Investment Opportunities
Discover IPOs, unlisted shares, and broker comparison tools curated for smart investors.